Endocrine effects of testosterone undecanoate as a supplementary treatment to menopausal gonadotropins or tamoxifen citrate in idiopathic oligozoospermia.

What Was Tested

The paper reports a study of Chorionic Gonadotropin and Tamoxifen, published as a controlled clinical trial.

To evaluate the effects of T undecanoate given as a supplementary treatment with tamoxifen citrate (TAM) or hMG on pituitary and Leydig cell function in men with idiopathic oligozoospermia.

Who Took Part

The study group was 48 men.

The age groups tagged for this paper are adults, men only.

All groups were evaluated with standard GnRH, thyrotropin-releasing hormone, and hCG tests before and on the final day of 3 months on treatment with measurements of FSH, LH, thyroid-stimulating hormone (TSH), PRL, T, E2, 17-hydroxyprogesterone, sex hormone-binding globulin, and seminal analyses (at least twice each time).

How the Study Was Run

The researchers set it up as a placebo-controlled study.

A placebo (an inactive look-alike) gave the Chorionic Gonadotropin group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Chorionic Gonadotropin, Follicle Stimulating Hormone, Gonadotropin-Releasing Hormone, Leydig Cells, Luteinizing Hormone, Menotropins and Oligospermia.

What This Means in Plain Language

The paper is a placebo-controlled study of Chorionic Gonadotropin and Tamoxifen in 48 men.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1995 (Fertility and sterility), a journal based in United States.

More context: the related hCG (human chorionic gonadotropin) library page, all human trials.